Beamion Lung 1, an ongoing phase Ia/Ib trial of the HER2 TKI, BI 1810631 in patients (pts) with advanced solid tumors with HER2 aberrations: Latest data

被引：2
|
作者：
Opdam, F. [1 ]
Heymach, J. [2 ]
Ruiter, G. [3 ]
Barve, M. [4 ]
Tu, H. [5 ]
Wu, Y-L. [5 ]
Schroeter, L. [6 ]
Sadrolhefazi, B. [7 ]
Serra, J. [8 ]
Yoh, K. [9 ]
Yamamoto, N. [10 ]
机构：
[1] Netherlands Canc Inst, Dept Clin Pharmacol, Amsterdam, Netherlands
[2] Univ Texas Houston, Div Canc Med, Dept Thorac Head & Neck Med Oncol, MD Anderson Canc Ctr, Houston, TX USA
[3] Netherlands Canc Inst, Antoni van Leeuwenhoek Hosp, Thorac Oncol & Phase 1 Studies, NKI AVL, Amsterdam, Netherlands
[4] Mary Crowley Canc Res Ctr, Dallas, TX USA
[5] Southern Med Univ, Guangdong Lung Canc Inst, Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci, Guangzhou, Peoples R China
[6] Boehringer Ingelheim Pharma GmbH & Co KG, Biostat & Data Sci, Biberach, Germany
[7] Boehringer Ingelheim Pharmaceut Inc, Oncol, Ridgefield, CT USA
[8] Boehringer Ingelheim SA, CD&O, Sant Cugat Del Valles, Spain
[9] Natl Canc Ctr Hosp East, Dept Thorac Oncol, Kashiwa, Chiba, Japan
[10] Natl Canc Ctr, Dept Thorac Oncol, Tokyo, Japan
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2408
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1375P
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Pharmacokinetics and pharmacodynamics of a HER2 tyrosine kinase inhibitor CP-724714 in patients with advanced malignant HER2 positive solid tumors.
    Guo, F
    Letrent, SP
    Noe, DA
    Qin, A
    Rohrbacher, KD
    Munster, PN
    Tolcher, AW
    Britten, CD
    Gelmon, K
    Sharma, A
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (02) : P10 - P10
  • [32] Population pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors
    Feng Guo
    Stephen P. Letrent
    Amarnath Sharma
    Cancer Chemotherapy and Pharmacology, 2007, 60 : 799 - 809
  • [33] Population pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors
    Guo, Feng
    Letrent, Stephen P.
    Sharma, Amarnath
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2007, 60 (06) : 799 - 809
  • [34] A phase 1b study of pertuzumab (P), a recombinant humanized antibody to HER2, and docetaxel (D) in patients (pts) with advanced solid tumors
    Attard, G
    Kitzen, JJ
    de Bono, J
    Verweij, J
    Pronk, L
    Zhi, J
    Blagden, SP
    Reade, SE
    Zugmaier, G
    de Jonge, MJ
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 232S - 232S
  • [35] A phase 3 randomized controlled trial of zongertinib (BI 1810631) compared with standard of care in patients with locally advanced or metastatic nonsquamous non-small cell lung cancer harboring HER2 tyrosine kinase domain mutations: Beamion LUNG-2
    Wu, Yi-Long
    Johnson, Melissa
    Soo, Ross
    Baktash, Navid
    Maier, Daniela
    Eigenbrod-Giese, Sabina
    Yoshida, Tatsuya
    CANCER RESEARCH, 2024, 84 (07)
  • [36] A population pharmacokinetic analysis of a HER2 tyrosine kinase inhibitor CP-724714 in patients with advanced malignant HER2 positive solid tumors.
    Guo, F
    Letrent, SP
    Sharma, A
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (02) : P54 - P54
  • [37] BIOMARKER ANALYSIS OF A PHASE 1 STUDY OF MM-111, A BISPECIFIC HER2/HER3 ANTIBODY FUSION PROTEIN, IN COMBINATION WITH MULTIPLE TREATMENT REGIMENS IN PATIENTS WITH ADVANCED HER2 POSITIVE SOLID TUMORS
    Kudla, A.
    Adiwijaya, B.
    Paragas, V.
    Richards, D.
    Braiteh, F.
    Garcia, A. A.
    Denlinger, C. S.
    Conkling, P.
    Edenfield, W. J.
    Anthony, S.
    Hellerstedt, B.
    Raju, R.
    Becerra, C.
    Harb, W.
    Smith, D.
    Kawash, K.
    Frye, S.
    McDonagh, C. F.
    Moyo, V.
    ANNALS OF ONCOLOGY, 2014, 25
  • [38] Phase I study of GQ1005, a new generation HER2-ADC, in patients with HER2-expressing and HER2 mutated advanced solid tumors
    Zhou, Caicun
    Yang, Bo
    Deng, Ting
    Wang, Biyun
    Zhang, Jian
    Sun, Yuping
    Wang, Linlin
    Yang, Hongwei
    Wang, Jingfen
    Li, Wei
    Song, Qi
    Yang, Yuchong
    CANCER RESEARCH, 2024, 84 (07)
  • [39] A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors
    N. Haense
    A. Atmaca
    C. Pauligk
    K. Steinmetz
    F. Marmé
    G. M. Haag
    M. Rieger
    O. G. Ottmann
    P. Ruf
    H. Lindhofer
    S.-E. Al-Batran
    BMC Cancer, 16
  • [40] A phase Ia study of a novel anti-HER2 antibody-drug conjugate GQ1001 in patients with previously treated HER2 positive advanced solid tumors
    Zhou, Chenfei
    Wang, Bin
    Teng, Christina
    Yang, Hui
    Piha-Paul, Sarina A.
    Richardson, Gary
    Malalasekera, Ashanya
    Sun, Yajun
    Wang, Wei
    Liu, Jieqiong
    Shi, Yan
    Zhan, Xianbao
    Lemech, Charlotte
    JOURNAL OF TRANSLATIONAL MEDICINE, 2025, 23 (01)
12345